Drug intelligence / Profile preview

moxifloxacin + penicillin

Development stage
Preclinical
Lead developer
Bayer
Modality
Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a combination of two antibiotics, moxifloxacin and penicillin. Moxifloxacin is a synthetic fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. Penicillins are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. This combination would theoretically provide broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria through dual mechanisms—disruption of DNA processes (moxifloxacin) and inhibition of cell wall synthesis (penicillin). While combinations of moxifloxacin with other beta-lactams like piperacillin-tazobactam have shown synergistic effects in vitro against certain resistant pathogens[5], there is no evidence for a fixed-dose or branded product specifically combining moxifloxacin with any penicillin.

02

Targets

PBP (Penicillin-binding protein family)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on moxifloxacin + penicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on moxifloxacin + penicillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call